Videos

Vincent Herrin, MD - University of Mississippi Medical Center Jackson, Mississippi

Arati Desai, MD, explains how the results from the phase III STELLAR trial will enhance knowledge of anaplastic astrocytoma.

A. Oliver Sartor, MD, discusses the current treatment options for patients with nonmetastatic castration-resistant prostate cancer (CRPC) and what physicians should consider when selecting treatment for their patients.

Scott Kopetz, MD, PhD, discusses the results of the phase III BEACON CRC study, which was presented at the 2020 Gastrointestinal Cancers Symposium.

Rashmi K. Murthy, MD, discusses the pivotal HER2CLIMB trial, which evaluated the addition of tucatinib to trastuzumab plus capecitabine in patients with HER2-positive metastatic breast cancer.

Ryan J. Sullivan, MD, compares the toxicity profiles of BRAF-targeted therapy and immunotherapy used for the treatment of patients with melanoma.

Jasmeet C. Singh, MD, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium.

Michael Wang, MD, discusses the approaches physicians can use when treating their patients with mantle cell lymphoma who have become resistant to cellular therapies, such as CAR T-cell therapy.

Ruben Mesa, MD, discusses the current state of the treatment landscape for patients with myeloproliferative neoplasms.